In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

The Medical University of South Carolina is expanding its access to state-supported Sickle Cell programs for “warriors,” or ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

RTCB is required for the splicing of both tRNA and XBP1 mRNA, whereas the DDX1 enzymatic activity is specifically required for tRNA splicing in vivo. Snaebjornsson et al. explore a selective ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also known as exa-cel, was the first treatment to be licensed using gene ...

In summary, our results demonstrate a role of endothelial Aquaporins in promoting water influx to increase endothelial tip cell volume and cytoplasmic hydrostatic pressure, as well as accelerate actin ...

In particular, the paper implicates hydrostatic pressure and water flow as mechanisms controlling endothelial cell migration during angiogenic sprouting. This important study significantly advances ...

It feels like the Splinter Cell remake has been on its way for a while now, which isn't helped by the fact it's been over three years since we heard anything official about the game. From what we ...

Sickle cell anaemia, a hereditary condition that primarily affects African and Mediterranean populations, continues to pose significant health challenges. In Uganda, where the disease is prevalent ...

Osivelotor is under clinical development by Pfizer and currently in Phase III for Sickle Cell Disease. According to GlobalData, Phase III drugs for Sickle Cell Disease have a 47% phase transition ...